Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson

NEW YORK, September 13, 2017 /PRNewswire/ --

If you want a Stock Review on ABBV, AZN, BMY, or JNJ then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. This morning, DailyStockTracker.com studies four major players in the Drug Manufacturers space: AbbVie Inc. (NYSE: ABBV), AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Co. (NYSE: BMY), and Johnson & Johnson (NYSE: JNJ). Demand for pharmaceuticals is driven by the desire to cure illness and disease. The profitability of individual drug manufacturing companies depends on their ability to discover and market new drugs. Daily Stock Tracker published free research reports on these stocks today at:

http://dailystocktracker.com/register/

AbbVie 

North Chicago, Illinois-based AbbVie Inc.'s shares gained 0.86%, closing Tuesday's trading session at $87.75. The stock recorded a trading volume of 11.15 million shares, which was above its three months average volume of 5.47 million shares. The Company's shares have surged 24.24% in the last month, 25.95% over the previous three months, and 40.13% since the start of this year. The stock is trading 20.31% above its 50-day moving average and 31.92% above its 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 89.92.  

On August 17^th, 2017, research firm Evercore ISI initiated an 'Outperform' rating on the Company's stock, with a target price of $95 per share.

On September 08^th, 2017, AbbVie's Board of Directors declared a quarterly cash dividend of $0.64 per share. The dividend is payable on November 15^th, 2017, to stockholders of record at the close of business on October 13^th, 2017. See our free and comprehensive research report on ABBV at:

http://dailystocktracker.com/registration/?symbol=ABBV

AstraZeneca 

On Tuesday, shares in Cambridge, the UK headquartered AstraZeneca PLC ("AZN") recorded a trading volume of 7.54 million shares, which was above their three months average volume of 5.05 million shares. The stock rose 1.30%, ending the day at $33.42. The Company's shares have advanced 14.92% in the past month and 22.33% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.11% and 9.83%, respectively. Furthermore, shares of AstraZeneca, which engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 74.60.  

On September 06^th, 2017, research firm Natixis Bleichroeder upgraded the Company's stock rating from 'Neutral' to 'Buy'.

On September 08^th, 2017, AZN and MedImmune, AZN's global biologics research and development arm, announced the full progression-free survival (PFS) data from a planned interim analysis of the investigational Phase-III PACIFIC trial. Results show that IMFINZI® (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in PFS compared to current standard of care with active surveillance in patients with locally-advanced (Stage III), unresectable non-small cell lung cancer who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy. AZN free research report is just a click away at:

http://dailystocktracker.com/registration/?symbol=AZN

Bristol Myers Squibb 

New York headquartered Bristol-Myers Squibb Co.'s stock finished the day 0.48% higher at $63.02 with a total trading volume of 4.78 million shares. The Company's shares have advanced 11.09% in the last one month, 16.29% in the previous three months, and 7.84% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.49% and 13.35%, respectively. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 77.47.  

On September 07^th, 2017, Bristol-Myers Squibb announced that it will report results for Q3 2017 on October 26^th, 2017. Company executives will host a conference call at 10:30 a.m. EDT on the same day to review financial information and address inquiries from investors and analysts. A live webcast of the call will be available on the Company's investor website.

On September 12^th, 2017, research firm Hilliard Lyons downgraded the Company's stock rating from 'Long-term Buy' to 'Neutral'. Sign up for your complimentary report on BMY at:

http://dailystocktracker.com/registration/?symbol=BMY

Johnson & Johnson 

Shares in New Brunswick, New Jersey-based Johnson & Johnson ended yesterday's session 0.44% lower at $132.63. The stock recorded a trading volume of 5.47 million shares, which was above its three months average volume of 5.42 million shares. The Company's shares have advanced 0.46% over the previous three months and 15.12% since the start of this year. The stock is trading 6.50% above its 200-day moving average. Moreover, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 51.44. Register for free on DailyStockTracker.com and download the latest research report on JNJ at:

http://dailystocktracker.com/registration/?symbol=JNJ

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com